Drug Profile
MVI 816
Alternative Names: PAP Vaccine - Madison Vaccines; pTVG-HP; pTVG-HP Plasmid DNA VaccineLatest Information Update: 11 Aug 2023
Price :
$50
*
At a glance
- Originator Madison Vaccines
- Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Prostate cancer
Most Recent Events
- 27 Jul 2023 Madison Vaccines and University of Wisconsin completes a phase I/II trial in Prostrate cancer (Combination therapy, Hormone refractory, Metastatic disease) in USA (Intradermal) (NCT02499835)
- 13 Sep 2022 Bristol-Myers Squibb discontinued phase II trial in Prostate cancer in USA (NCT03600350)
- 28 Sep 2021 MVI 816 is still in phase II trials for Prostrate cancer (Combination therapy, Hormone refractory, Metastatic disease) in USA (Intradermal)